Senolytic Drug Combo Slows Age-Related Hearing Loss in Mice
Dasatinib and quercetin clear senescent cochlear cells, reducing inflammation and preserving hair cells in aging mice.
Summary
Age-related hearing loss affects millions of older adults, yet few treatments target its root biological causes. Researchers tested dasatinib and quercetin — a well-known senolytic drug combination — in aging mice to see whether clearing senescent cells from the inner ear could slow hearing decline. The treatment significantly delayed hearing loss progression and reduced degeneration of cochlear hair cells in both male and female mice. Even mice with normal hearing showed less age-related hair cell loss when treated early. In lab studies, the combination reduced the harmful inflammatory signals that senescent cells release. The mechanism appears to involve blocking NF-κB, a key inflammatory pathway. These findings suggest senolytics could one day offer a novel strategy for preventing or slowing age-related hearing loss in humans.
Detailed Summary
Age-related hearing loss (ARHL) is one of the most common sensory impairments in older adults, affecting quality of life and increasing risk of cognitive decline. Despite its prevalence, effective disease-modifying treatments remain elusive. This study investigates whether cellular senescence — a hallmark of biological aging in which damaged cells stop dividing but release harmful inflammatory signals — plays a meaningful role in cochlear degeneration and hearing decline.
Researchers from Sun Yat-sen University administered dasatinib and quercetin (D+Q), a widely studied senolytic combination, to C57BL/6J mice at different stages of age-related hearing loss. This mouse strain is a standard model for ARHL research. The team assessed hearing function, cochlear structure, and cellular senescence markers across treatment groups, and also tested D+Q in HEI-OC1 auditory cell cultures and cochlear explants.
The results were notable. Mice treated with D+Q at an early stage of ARHL showed significantly delayed hearing loss progression and reduced cochlear degeneration compared to untreated controls. Importantly, mice with still-normal hearing also benefited, showing less age-related hair cell loss — suggesting a preventive as well as therapeutic window. In cell culture, D+Q reduced the senescence-associated secretory phenotype (SASP), the inflammatory cocktail that senescent cells release and that damages surrounding tissue.
Transcriptomic analysis of cochlear explants revealed that D+Q treatment downregulated inflammatory cytokines and chemokines. Mechanistically, the drugs appeared to bind to NF-κB and inhibit its activity, dampening the inflammatory cascade that drives cochlear aging.
These findings position senolytics as a promising therapeutic avenue for ARHL. However, the study is limited to a mouse model, and translation to human cochlear biology requires further validation. The abstract-only access also limits full methodological appraisal.
Key Findings
- Dasatinib + quercetin significantly delayed age-related hearing loss progression in aging C57BL/6J mice.
- Early treatment preserved cochlear hair cells even in mice with still-normal hearing.
- D+Q reduced the senescence-associated secretory phenotype (SASP) in auditory cells.
- Mechanism involves NF-κB inhibition, dampening cochlear inflammatory signaling.
- Transcriptomics confirmed downregulation of inflammatory cytokines and chemokines in treated cochlear tissue.
Methodology
The study used C57BL/6J mice, a standard ARHL model, treated with dasatinib and quercetin at different disease stages. Outcomes included hearing function tests, cochlear histology, cell culture experiments in HEI-OC1 auditory cells, and transcriptomic analysis of cochlear explants. Both male and female mice were included.
Study Limitations
This study is conducted entirely in mice and cell culture models; human cochlear biology may differ significantly. The summary is based on the abstract only, limiting full assessment of methodology, sample sizes, and statistical rigor. Long-term safety and efficacy of senolytic treatment specifically for hearing preservation have not been evaluated in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.